EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk, whose profits from blockbuster weight-loss ...

Danish pharmaceutical giant Novo Nordisk sees a significant increase in profits and sales despite production constraints.

"This is a forward-looking statement, mathematically based, and we'll come back with the more detailed guidance come early February 2025," Knudsen said. He said that absolute sales growth last year ...

Evotec AG (EVO) has released an update. Evotec AG’s recent financial performance showed a slight revenue decline of 1% to €575.7 million, ...

Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...

Danish pharmaceutical giant Novo Nordisk, maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, posted Wednesday strong third-quarter earnings despite being held back by ...

The FTSE 100 was 0.07% lower at 8,166, Germany's DAX down 1.14% at 19,036, France's CAC 0.51% lower at 7,369 and ... boosted ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Novo Nordisk has asked the Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex ...

Novo Nordisk landed in hot water with the FDA following an inspection at one of the drugmaker’s key semaglutide and insulin manufacturing plants this past spring. | The FDA issued a ...

For U.S. investors who are worried that domestic stocks are overheated and have gotten too expensive, the iShares Core MSCI ...